Clinical trial · Observational
Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
NCT01792882CI-TRIAL-00064318GBCPRT0008withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is intended to collect specimens to support the application of genome analysis technologies, including large-scale genome sequencing. This study will ultimately provide cancer researchers with specimens that they can use to develop comprehensive catalogs of genomic information on at least 50 types of human cancer. The study will create a resource available to the worldwide research community that could be used to identify and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies. This study will be a competitive enrollment study conducted at multiple institutions.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Hematologic Cancer | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cancer Subjects
Primary outcomes (1)
- measure
- Tumor genetic sequence variation
- timeFrame
- up to 18 months
- description
- The specimens collected for this project will support genomic studies on the molecular basis of cancer. This study aims to collect specimens for a project that will systematically explore a spectrum of genomic changes involved in human cancer. Specifically the project will analyze DNA copy number changes, including large (on the order of chromosomal segments) and small (1,000 to 100,000 KB) scale rearrangements, transcription profiles, epigenetic modifications, sequence variation, and sequence in both tumor tissue and case-matched germline DNA. The suite of analysis platforms for collaborating laboratories will be applied to a common set of molecular analytes obtained from clinically annotated high-quality tumor specimens and case matched normal control specimens obtained form this specimen collection study. Initial measures critical to ensure specimen quality and qualification for subsequent analysis include confirmed histopathology and RNA integrity.
Secondary outcomes (1)
- measure
- Transcription profile
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Any adult age * Any sex * Able to provide consent for surplus tissue and/or blood donation * Diagnosed with one of the cancer indications listed below: * Scheduled to undergo surgical resection of tumor (exception for hematological cancers) * Have not yet received treatment for cancer Exclusion Criteria: * Not diagnosed with required cancer indication * Not scheduled to undergo surgical resection of the tumor * Have already received cancer treatment (such as chemotherapy, radiation, surgery) for the current cancer or a previously diagnosed cancer * Not able to donate an adequate volume of blood to meet minimum requirements CANCER INDICATIONS: 1. Bladder Cancer - Urothelial carcinoma - nonpapillary 2. Bladder Cancer - Urothelial carcinoma - papillary 3. Brain Cancer - Astrocytoma 4. Brain Cancer - Glioblastoma 5. Brain Cancer - Medulloblastoma 6. Breast Cancer - Ductal Carcinoma 7. Breast Cancer - Lobular Carcinoma 8. Cervical Cancer - Squamous Cell Carcinoma 9. Colorectal Cancer - Adenocarcinoma 10. Esophageal Cancer - Adenocarcinoma 11. Gastric Cancer 12. Head and Neck Cancer - Squamous Cell Carcinoma 13. Hematologic Cancer - Acute Lymphocytic Leukemia (ALL) 14. Hematologic Cancer - Acute Myeloid Leukemia (AML) 15. Hematologic Cancer - Chronic Lymphocytic Leukemia (CLL) 16. Hematologic Cancer - Diffuse Large B-cell Lymphoma 17. Hematologic Cancer - Multiple Myeloma (MM) 18. Hematologic Cancer - Non-Hodgkins Lymphoma (NHL) 19. Kidney Cancer - Papillary Carcinoma 20. Kidney Cancer - Renal cell Carcinoma 21. Liver Cancer - Hepatocellular Carcinoma 22. Lung Cancer - Adenocarcinoma 23. Lung Cancer - Squamous Cell Cancer 24. Melanoma 25. Pancreatic Cancer - Ductal Adenocarcinoma 26. Prostate Cancer - Adenocarcinoma 27. Sarcomas 28. Thyroid Cancer - Follicular Carcinoma 29. Thyroid Cancer - Papillary Carcinoma 30. Uterine Cancer - Endometrial Carcinoma
References
Publications (0)
Data not yet available
No reference posted for this study.